SEARCH

SEARCH BY CITATION

References

  • Abramson, J.S. & Shipp, M.A. (2005) Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood, 106, 11641174.
  • Ackland, S.P., Ratain, M.J., Vogelzang, N.J., Choi, K.E., Ruane, M. & Sinkule, J.A. (1989) Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clinical Pharmacology and Therapeutics, 45, 340347.
  • Armitage, J.O., Carbone, P.P., Connors, J.M., Levine, A., Bennett, J.M. & Kroll, S. (2003) Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. Journal of Clinical Oncology, 21, 897906.
  • Aviles, A., Fernandez, R., Perez, F., Nambo, M.J., Neri, N., Talavera, A., Castaneda, C., Gonzalez, M. & Cleto, S. (2004) Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leukemia and Lymphoma, 45, 13851389.
  • Brusamolino, E., Rusconi, C., Montalbetti, L., Gargantini, L., Uziel, L., Pinotti, G., Fava, S., Rigacci, L., Pagnucco, G., Pascutto, C., Morra, E. & Lazzarino, M. (2006) Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica, 91, 496502.
  • Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346, 235242.
  • Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F & Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 41174126.
  • Gisselbrecht, C., Lepage, E., Molina, T., Quesnel, B., Fillet, G., Lederlin, P., Coiffier, B., Tilly, H., Gabarre, J., Guilmin, F., Hermine, O. & Reyes, F. (2002) Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. Journal of Clinical Oncology, 20, 24722479.
  • Gutierrez, M., Chabner, B.A., Pearson, D., Steinberg, S.M., Jaffe, E.S., Cheson, B.D., Fojo, A. & Wilson, W.H. (2000) Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. Journal of Clinical Oncology, 18, 36333642.
  • Haioun, C., Lepage, E., Gisselbrecht, C., Salles, G., Coiffier, B., Brice, P., Bosly, A., Morel, P., Nouvel, C., Tilly, H., Lederlin, P., Sebban, C., Briere, J., Gaulard, P. & Reyes, F. (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87 – 2 protocol – a groupe d'Etude des lymphomes de l'Adulte study. Journal of Clinical Oncology, 18, 30253030.
  • Halaas, J.L., Moskowitz, C.H., Horwitz, S., Portlock, C., Noy, A., Straus, D., O'Connor, O.A., Yahalom, J. & Zelenetz, A.D. (2005) R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leukemia and Lymphoma, 46, 541547.
  • Hryniuk, W. & Bush, H. (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. Journal of Clinical Oncology, 2, 12811288.
  • Isasi, C.R., Lu, P. & Blaufox, M.D. (2005) A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer, 104, 10661074.
  • Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (2001) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon.
  • Kluin-Nelemans, H.C., Zagonel, V., Anastasopoulou, A., Bron, D., Roozendaal, K.J., Noordijk, E.M., Musson, H., Teodorovic, I., Maes, B., Carbone, A., Carde, P. & Thomas, J. (2001) Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. Journal of the National Cancer Institute, 93, 2230.
  • Knight, C., Hind, D., Brewer, N. & Abbott, V. (2004) Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Health Technology Assessment, 8, 182.
  • Komrokji, R.S., Uppal, N.P., Khorana, A.A., Lyman, G.H., Kaplan, K.L., Fisher, R.I. & Francis, C.W. (2006) Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 47, 10291033.
  • Miller, A.B., Hoogstraten, B., Staquet, M. & Winkler, A. (1981) Reporting results of cancer treatment. Cancer, 47, 207214.
  • Milpied, N., Deconinck, E., Gaillard, F., Delwail, V., Foussard, C., Berthou, C., Gressin, R., Lucas, V., Colombat, P. & Harousseau, J.L. (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. The New England Journal of Medicine, 350, 12871295.
  • Mohren, M., Markmann, I., Jentsch-Ullrich, K., Koenigsmann, M., Lutze, G. & Franke, A. (2005) Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. British Journal of Cancer, 92, 13491351.
  • Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A.C., Rudolph, C., Reiser, M., Hossfeld, D.K., Metzner, B., Hasenclever, D., Schmitz, N., Glass, B., Rube, C. & Loeffler, M. (2004a) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood, 104, 626633.
  • Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A.C., Rudolph, C., Reiser, M., Hossfeld, D.K., Eimermacher, H., Hasenclever, D., Schmitz, N. & Loeffler, M. (2004b) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood, 104, 634641.
  • Pfreundschuh, M., Kloess, M., Schmits, R., Zeynalova, S., Lengfelder, E., Fanke, A., Steinhauer, H., Reiser, M., Clemens, M., Nickenig, C., De Wit, M., Hoffmann, M., Mertelsmann, R., Metzner, B., Ho, A., Truemper, L., Eimermacher, H., Mergenthaler, H., Liersch, R., Duehrsen, U., Balleisen, L., Hartmann, F., Poeschel, V., Schmitz, N. & Loeffler, M. (2005) Six, not eight cycles of bi-weekly CHOP with Rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood, 106, 13a (abstract).
  • Relling, M.V., Boyett, J.M., Blanco, J.G., Raimondi, S., Behm, F.G., Sandlund, J., Rivera, G.K., Kun, L.E., Evans, W.E. & Pui, C.H. (2003) Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood, 101, 38623867.
  • Rigacci, L., Nassi, L., Alterini, R., Carrai, V., Longo, G., Bernardi, F., Martini, V. & Bosi, A. (2006) Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study. Acta Haematologica, 115, 2227.
  • Shipp, M.A. & Harrington, D.P. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New England Journal of Medicine, 329, 987994.
  • Tilly, H., Lepage, E., Coiffier, B., Blanc, M., Herbrecht, R., Bosly, A., Attal, M., Fillet, G., Guettier, C., Molina, T.J., Gisselbrecht, C. & Reyes, F. (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 102, 42844289.
  • Vose, J.M., Bierman, P.J. & Armitage, J.O. (2003) Diagnosis and treatment of non-Hodgkin's lymphoma of adults. In: Neoplastic Diseases of the Blood 4th edn (ed. by P.H.Wiernik, J.M.Goldman, J.P.Dutcher & R.A.Kyle), pp. 827842. Cambridge University Press, Cambridge.
  • Wilder, R.B., Rodríguez, M.A., Ha, C.S., Pro, B., Hess, M.A., Cabanillas, F. & Cox, J.D. (2001) Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer, 91, 24402446.
  • Wilson, W.H., Grossbard, M.L., Pittaluga, S., Cole, D., Pearson, D., Drbohlav, N., Steinberg, S.M., Little, R.F., Janik, J., Gutierrez, M., Raffeld, M., Staudt, L., Cheson, B.D., Longo, D.L., Harris, N., Jaffe, E.S., Chabner, B.A., Wittes, R. & Balis, F. (2002a) Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood, 99, 26852693.
  • Wilson, W.H., Gutierrez, M., O'Connor, P., Frankel, S., Jaffe, E., Chabner, B.A. & Grossbard, M.L. (2002b) The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Seminars in Oncology, 29 (Suppl. 2), 4147.